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Abstract
Peripheral neuropathy (PN) is a debilitating and dose-limiting side effect of treatment with the 
chemotherapeutic agent, paclitaxel. Understanding the effects of paclitaxel on sensory neuronal 
function and the signaling pathways which mediate these paclitaxel-induced changes in function 
are critical for the development of therapies to prevent or alleviate the PN. The effects of long-
term administration of paclitaxel on the function of sensory neurons grown in culture, using the 
release of the neuropeptide calcitonin gene-related peptide (CGRP) as an endpoint of sensory 
neuronal function, were examined. Dorsal root ganglion cultures were treated with low (10 nM) 
and high (300 nM) concentrations of paclitaxel for 1, 3, or 5 days. Following paclitaxel treatment, 
the release of CGRP was determined using capsaicin, a TRPV1 agonist; allyl isothiocyanate 
(AITC), a TRPA1 agonist; or high extracellular potassium. The the effects of paclitaxel on the 
release of CGRP were stimulant-, concentration-, and time-dependent. When neurons were 
stimulated with capsaicin or AITC, a low concentration of paclitaxel (10 nM) augmented 
transmitter release, whereas a high concentration (300 nM) reduced transmitter release in a time-
dependent manner; however, when high extracellular potassium was used as the evoking stimulus, 
all concentrations of paclitaxel augmented CGRP release from sensory neurons. These results 
suggest that paclitaxel alters the function of sensory neurons in vitro, and suggest that the 
mechanisms by which paclitaxel alters neuronal function may include functional changes in TRP 
channel activity. The described in vitro model will facilitate future studies to identify the signaling 
pathways by which paclitaxel alters neuronal sensitivity.
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Introduction
Paclitaxel is a chemotherapeutic microtubule targeting agent that is commonly used in the 
treatment of breast, ovarian, and lung cancers (Rowinsky et al., 1991). Although paclitaxel is 
an effective antineoplastic, its use is often limited by severe side effects including peripheral 
neuropathy (PN). Paclitaxel-induced PN is characterized by burning pain, numbness, 
tingling in the hands and feet, and loss of proprioception (Dougherty et al., 2004; Forsyth et 
al., 1997; Lipton et al., 1989; Wiernik et al., 1987). Although these symptoms resolve in 
some patients following cessation of treatment, they may be irreversible and can persist as 
chronic neuropathic pain (Connelly et al., 1996). There are no known treatment options 
which specifically prevent or reverse the neuropathy, and most patients resort to scaling back 
the bolus of paclitaxel per treatment or to discontinuing administration of paclitaxel entirely 
to minimize symptoms of the neuropathy (Capri et al., 1996). Although it is clear that 
chronic administration of paclitaxel alters the function of sensory neurons, the questions 
remain whether the drug augments or reduces neuronal sensitivity and what are the cellular 
mechanisms by which the drug affects neuronal function. Indeed, it is critical to understand 
how paclitaxel alters the function of sensory neurons and whether it differentially affects 
subpopulations of sensory neurons before therapies can be developed to alleviate paclitaxel-
induced PN.
There are several animal models to examine the in vivo effects of paclitaxel on neuronal 
activity. A low-dose model, whereby paclitaxel (cumulative doses of 4, 8, or 16 mg/kg) is 
injected systemically over the course of 7 days, results in mechanical hyperalgesia and 
allodynia, as well as cold allodynia, without causing overt nerve damage, alterations in nerve 
conduction velocity, or changes in neuronal survival (Flatters and Bennett, 2006; Matsumoto 
et al., 2006; Polomano et al., 2001). These data suggest that the sensitivity of sensory nerve 
fibers (unmyelinated C-fibers and lightly myelinated Aδ-fibers) is enhanced after paclitaxel 
treatment. In contrast, using vasodilatation induced by activation of peripheral endings of 
sensory neurons as an endpoint to indirectly measure the activity of small diameter sensory 
nerve fibers innervating vascular smooth muscle in the dermis, we showed that the same 
low-dose paclitaxel treatment that produces hyperalgesia reduced vasodilatation induced by 
the activation of sensory neurons by capsaicin (Gracias et al., 2011). In an alternative animal 
model, paclitaxel (cumulative doses of 80–135 mg/kg) is injected systemically over the 
course of 5–9 weeks. This model produces impairments in pain-like behaviors using the tail-
flick test and thermal withdrawal latencies as endpoints, decreases in coordination as 
measured by the rota-rod test, and decreases in nerve conduction velocity in the tail nerve 
with variable axonal damage, suggesting a reduced sensitivity of sensory neurons (Authier et 
al., 2000; Cavaletti et al., 1997). These data suggest that, dependent upon the endpoint 
measured and the dosing paradigm administered, both increases and decreases in neuronal 
sensitivity occur; however, investigators still do not have a clear understanding of what 
population of neurons is affected and the mechanisms by which these changes in sensitivity 
develop.
Treating sensory neuron cultures or explants with paclitaxel induces shortening of neurite 
lengths (Melli et al., 2008; Scuteri et al., 2006; Yang et al., 2009); however, mechanistic in 
vitro studies to examine the effects of paclitaxel on the sensitivity of subpopulations of 
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sensory neurons are limited. Several investigators have isolated the lumbar dorsal root 
ganglia from paclitaxel-treated animals to examine the effects of the chemotherapeutic on 
electrical excitability and intracellular calcium signaling within the soma of the lumbar 
neurons, which predominantly innervate the hindpaws (Kawakami et al., 2012; Mo et al., 
2012; Zhang et al., 2013). While this experimental paradigm works well for measuring 
excitability and intracellular calcium signaling in the soma, it does not permit investigation 
of the effects of paclitaxel on an integrated neuronal response, such as the stimulated release 
of neurotransmitters from the neurites and soma of sensory neurons. Therefore, we 
examined the effects of paclitaxel treatment on the function of sensory neurons grown in 
culture. Previous studies have demonstrated a direct excitatory effect of paclitaxel on 
neuropeptide release (Materazzi et al., 2012; Miyano et al., 2009); however, most patients do 
not feel pain during paclitaxel infusion. Since the clinical onset of symptoms occurs 3–6 
weeks following the first dose of paclitaxel (Forsyth et al., 1997), we examined the effects of 
paclitaxel at timepoints distant from the start of drug exposure: 1, 3 and 5 days following 
treatment with paclitaxel.
We determined the effects of paclitaxel on the basal and evoked release of the nociceptive 
neuropeptide, calcitonin gene-related peptide (CGRP), from sensory neuron cultures as an 
indicator of sensory neuronal function (Vasko et al., 1994). We evoked the release of CGRP 
from the sensory neurons with 3 different stimulatory agents in order to gain mechanistic 
insight into the paclitaxel-induced changes within our cultures. We used a TRPV1 agonist, 
capsaicin, since we previously showed that capsaicin-induced bloodflow was altered by 
paclitaxel treatment (Gracias et al., 2011) and because systemic administration of a TRPV1 
antagonist has been shown to attenuate thermal hyperalgesia following paclitaxel treatment 
(Chen et al., 2011). We also used a TRPA1 agonist, allyl isothiocyanate (AITC), since 
systemic administration of a TRPA1 antagonist reduces paclitaxel-induced mechanical and 
cold allodynia (Chen et al., 2011; Materazzi et al., 2012). Finally, we utilized a general 
depolarizing stimulus, high extracellular potassium, to examine the effects of paclitaxel 
treatment on the sensitivity of neurons independent of TRP channel activation. We found 
that paclitaxel alters the sensitivity of isolated sensory neurons in a concentration- and time-
dependent manner. Paclitaxel can enhance or reduce capsaicin- and AITC-evoked release of 
CGRP depending on the magnitude and duration of exposure to the chemotherapeutic. In 
contrast, paclitaxel augments CGRP release evoked by high extracellular potassium, 
regardless of the concentration or duration of paclitaxel exposure. Our findings support a 
role for small diameter sensory neurons in paclitaxel-induced neurotoxicity and suggest that 
the mechanisms by which paclitaxel alters neuronal function may include functional changes 
in TRP channel activity. Furthermore, the described in vitro model will facilitate future 
studies to identify the signaling pathways by which paclitaxel alters neuronal sensitivity.
Methods
Animals
All animal experiments were carried out in accordance with the Animal Care and Use 
Committee at Indiana University School of Medicine, Indianapolis, IN and with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. All experiments 
PITTMAN et al. Page 3
Exp Neurol. Author manuscript; available in PMC 2018 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
were performed on primary cultures of sensory neurons derived from the dorsal root ganglia 
(DRG) of adult male Sprague Dawley rats (150–250 g; Harlan Laboratories, Indianapolis, 
IN). Prior to sacrifice, animals were housed in group cages in a light controlled room. Food 
and water were available ad libitum.
Isolation of primary sensory neuron cultures
Dorsal root ganglia (DRG) were harvested and cultured as described previously with slight 
modifications (Hingtgen and Vasko, 1994). Rats were asphyxiated with CO2 and then 
decapitated. DRG were harvested from the vertebral column, and the sensory neurons were 
dissociated by mechanical agitation after incubation for 1 hour in 0.125% collagenase at 
37°C. Approximately 30,000 cells were plated into each well of a 12-well plate previously 
coated with poly-d-lysine and laminin. Cells were grown in F-12 growth media 
supplemented with 10% heat-inactivated horse serum, 2 mM glutamine, 50 μg/ml penicillin 
and streptomycin, 50 μM 5-fluoro-2-deoxyuridine, and 150 μM uridine in the presence of 30 
ng/ml nerve growth factor (NGF). This concentration of NGF has previously been shown to 
enhance the expression of CGRP without compromising the ability of neurons to be 
sensitized by inflammatory mediators (Park et al., 2010). Cultures were maintained in an 
atmosphere of 3% CO2 at 37°C and media was changed every other day. For paclitaxel 
treatments, a stock of 10 mM paclitaxel was prepared in 1-methyl-2-pyrrolidinone (MPL) 
and stored at −20°C. This stock was further diluted in media to appropriate concentrations of 
paclitaxel. Cultures were treated with paclitaxel in media starting on day 7, 9, or 11 in 
culture, and experiments were performed on day 12 in culture.
Calcitonin gene-related peptide release
Release experiments were performed as described previously (Hingtgen and Vasko, 1994; 
Vasko et al., 1994). The wells were rinsed one time with HEPES buffer containing 25 mM 
HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 3.3 mM D-glucose, and 
0.1% bovine serum albumin, pH 7.4. The cells were maintained at 37°C for 4, 10 min 
incubations. During the first and second 10 min intervals, cells were incubated with HEPES 
buffer to establish resting basal release of immunoreactive CGRP (iCGRP), which we will 
refer to as CGRP.
During the third interval, cells were incubated with HEPES containing 30 nM capsaicin, 
HEPES containing 30 μM AITC, or HEPES containing 50 mM KCl (substituted for 
equimolar NaCl) in order to stimulate CGRP release. The fourth incubation was in HEPES 
to reestablish resting basal release. Supernatants were collected after every interval, and 
CGRP was measured using radioimmunoassay as previously described (Vasko et al., 1994). 
At the completion of the release experiment, cells were incubated for 20 min in 0.1 N HCl, 
and the supernatant was collected to determine total CGRP content.
Viability assay
The viability of sensory neurons following exposure to paclitaxel was assessed by double 
staining with propidium iodide (PI) and annexin V. Sensory neuronal cultures were exposed 
to either 300 nM or 1 μM paclitaxel for 5 days. As a positive control, untreated neurons were 
exposed to 300 μM H2O2 for 1 hour at 37°C. At the end of the 1-hour incubation, the 
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neurons were returned to F-12 media. Approximately 24 hours later, all neurons were 
incubated with 0.4 ml of the staining solution containing 25μl annexin V-FITC in 10 ml 
HEPES buffer and 6 μM PI. After washing off the staining solution, cells were visualized. 
The excitation of PI/annexin V was 530/485 nm and the emitted light was monitored at 
645/530 nm. After staining with PI and annexin V, nuclei appear red while cells that are in 
the initial stages of apoptosis display a green colored ring around the cells. Dead cells 
display more diffuse staining with annexin V. Neurons in five random fields were counted 
and scored as either viable (unstained) or non-viable (red or green). The data are expressed 
as mean ± standard error of the mean (SEM) % of the total number of neurons counted.
Reagents
All materials unless stated otherwise were purchased from Sigma-Aldrich (St. Louis, MO). 
F-12 media, horse serum, antibiotics, and annexin V-FITC were purchased from Invitrogen 
(Carlsbad, CA). The AITC was purchased from Fisher Scientific (Pittsburgh, PA), and nerve 
growth factor was purchased from Harlan Laboratories (Indianapolis, IN).
Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA) or two-way ANOVA as 
indicated, and post-hoc analyses were performed using the Bonferroni’s or Dunnett’s test, as 
indicated. Statistical calculations were performed with the GraphPad Prism version 6.02 
statistical package (GraphPad Software, La Jolla, California USA). Data are presented as 
mean ± SEM, and differences are considered significant if p < 0.05.
Results
The effects of paclitaxel on basal and stimulated release of CGRP
Our previous results suggest that systemic administration of paclitaxel reduces the sensitivity 
of small diameter sensory neurons (Gracias et al., 2011), whereas other findings suggest an 
increase in sensitivity (Flatters and Bennett, 2006; Matsumoto et al., 2006; Polomano et al., 
2001). To determine the direct effects of long-term paclitaxel exposure on sensory neurons, 
we cultured sensory neurons for 5 days in the presence of various concentrations of 
paclitaxel. We then measured the basal release of CGRP and the release of CGRP upon 
stimulation with 30 nM capsaicin. Five-day treatment with vehicle (.003% MPL), 10 nM or 
300 nM paclitaxel did not alter the resting basal release of CGRP (first B column of each 
treatment group, Figure 1A). Five-day treatment with 10 nM paclitaxel did enhance the 
stimulated release of CGRP. Capsaicin stimulated the release of CGRP from a basal level of 
29 ± 2 fmol/well/10min to 274 ± 23 fmol/well/10min in vehicle-treated neurons (Figure 
1A). The capsaicin-evoked release was augmented to 329 ± 24 fmol/well/10min in neurons 
treated with 10 nM paclitaxel (C columns, Figure 1A). In contrast, treatment with 300 nM 
paclitaxel significantly decreased capsaicin-evoked release to 150 ± 9 fmol/well/10min. The 
changes in release of CGRP were not secondary to an altered content of CGRP in the 
neurons, as the total content of CGRP was similar in cultures treated with vehicle (1207 ± 80 
fmol/well), 10 nM paclitaxel (1359 ± 97), or 300 nM paclitaxel (1165 ± 59; Figure 1B). We 
also examined other concentrations of paclitaxel: exposure of sensory neurons in culture to 
30 nM paclitaxel for 5 days augmented capsaicin-evoked CGRP release by 20%, whereas 
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exposure to 100 nm or 1 μM reduced release by 45% and 75%, respectively (data not 
shown).
Capsaicin stimulates the release of neuropeptides from small diameter sensory neurons 
expressing the TRPV1 receptor (Holzer, 1988) by increasing the permeability of the channel 
and inducing an inward calcium current. To determine if paclitaxel alters the function of the 
TRPA1 channel, we stimulated the sensory neurons with 30 μM AITC, a TRPA1 agonist, 
after treatment with 10 or 300 nM paclitaxel for 5 days. AITC-evoked CGRP release was 
significantly greater from neurons treated with 10 nM paclitaxel as compared to vehicle-
treated neurons: the stimulated release was increased from 347 ± 26 fmol/well/10min in 
vehicle-treated neurons to 472 ± 29 fmol/well/10min in neurons treated with 10 nM 
paclitaxel (Figure 2A). Treatment for 5 days with 300 nM paclitaxel decreased AITC-evoked 
release to 117 ± 16 fmol/well/10min (Figure 2A). Total CGRP content in the neurons was 
not changed by paclitaxel treatment. Content levels were 1107 ± 77 fmol/well, 1343 ± 93 
fmol/well, and 895 ± 85 fmol/well in the vehicle, 10 nM, and 300 nM-treated groups, 
respectively (Figure 2B).
To examine whether the effects of paclitaxel were dependent on altered sensitivity of TRP 
channels, we stimulated neuronal cultures treated with vehicle, 10 nM paclitaxel or 300 nM 
paclitaxel for 5 days with a general depolarizing stimulus, 50 mM potassium. In vehicle-
treated cultures, high extracellular potassium increased the release of CGRP from basal 
levels of 25 ± 2 fmol/well/10min to 291 ± 12 fmol/well/10min (open vs shaded HK 
columns, Figure 3A). Exposing cultures to 10 nM paclitaxel for 5 days resulted in an 
increase in the potassium-stimulated release of CGRP to 353 ± 16 fmol/well/10min without 
altering resting basal release in a manner analogous to that observed when release was 
stimulated by the TRP channel agonists (Figure 3A). In contrast to our results with 
capsaicin- and AITC-evoked release, exposing cultures to 300 nM paclitaxel for 5 days also 
augmented the CGRP release evoked by potassium to 346 ± 16 fmol/well/10min (Figure 
3A). Differences in potassium-evoked release were not due to an alteration of neuropeptide 
content, as total contents for the vehicle, 10 nM, and 300 nM treated cultures were 1219 
± 78 fmol/well, 1277 ± 87 fmol/well, and 1190 ± 63 fmol/well, respectively (Figure 3B).
The effects of paclitaxel on neuronal viability
Previous reports demonstrate that paclitaxel treatment can cause significant neuronal death 
in DRG cultures derived from embryonic day 16 (E16) rats and that this death is mediated 
through necrosis (Scuteri et al., 2006). To determine whether paclitaxel’s alteration in 
transmitter release could be secondary to a change in sensory neuronal viability in adult 
DRG cultures, we stained neuronal cultures with propidium iodide (PI) to differentiate 
between live and dead cells and with annexin V to determine if cells were in the initial 
stages of apoptosis. In cultures treated with vehicle for 5 days, the percentage of neurons 
that stained positive for annexin V or PI was 8 ± 2 % and 8 ± 2% of the total number of 
neurons counted, respectively (Figure 4). In cultures exposed to 300 nM paclitaxel for 5 
days, the percentage of neurons that stained positive for annexin V or PI were 10 ± 2% and 
10 ± 3 % of the total number of neurons counted. Five days of exposure to 1 μM paclitaxel 
also did not significantly affect cell viability (Figure 4). As a positive control for decreases 
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in cell viability, neuronal cultures were exposed to 300 μM H2O2 for 1 hour at 37°C, which 
has previously been shown to produce significant loss in cell viability (Vasko et al., 2005). 
As seen in Figure 4, H2O2 treatment significantly increased the percentage of annexin V and 
PI positive cells to 63 ± 14% and 69 ± 18% of the total number of neurons, respectively.
The time-course of paclitaxel-induced changes in basal and stimulated CGRP release
To investigate if paclitaxel-induced alterations in capsaicin-evoked CGRP release were 
dependent on the duration of paclitaxel exposure, we treated sensory neuronal cultures with 
10 nM or 300 nM paclitaxel for 1, 3, or 5 days or with vehicle for 5 days. We then measured 
the basal release of CGRP and release upon stimulation with 30 nM capsaicin. The treatment 
with vehicle (.003% MPL), 10 nM or 300 nM paclitaxel did not alter the resting basal 
release of CGRP (B columns, Figures 5A and 6A) over the course of treatment. The 
capsaicin-evoked CGRP release from neurons treated with 10 nM paclitaxel for 1 day did 
not differ from the vehicle controls; the release was 339 ± 11 and 353 ± 10 fmol/well/10min 
in the vehicle and treated neurons, respectively (C columns, Figure 5A). However, the 
capsaicin-evoked CGRP release from the 3 day and 5 day 10 nM paclitaxel-treated wells 
significantly increased to 380 ± 14 and 395 ± 17 fmol/well/10min, respectively. The increase 
in capsaicin-evoked release of iCGRP was not secondary to an altered content of CGRP in 
the neurons since treatments with 10 nM paclitaxel did not alter the content of the peptide in 
the cultures (Figure 5B).
We also observed a small, but significant augmentation in the capsaicin-evoked release of 
CGRP following 1 day of exposure of neuronal cultures to 300 nM paclitaxel. The release of 
CGRP in vehicle- and paclitaxel-treated neurons was 328 ± 9 and 369 ± 15 fmol/well/
10min, respectively (C columns, Figure 6A). This increase in CGRP release, however, was 
likely because of an increase in the content of CGRP in the cultures, since 300 nM paclitaxel 
increased the peptide content levels from 1470 ± 30 to 1623 ± 40 (Figure 6B). Calculating 
the capsaicin-stimulated release as the % of total peptide content, release from vehicle-
treated neurons was 22%, and it was 23% from cultures treated with 300 nM paclitaxel for 1 
day. Following 3 or 5 days of treatment with paclitaxel (300 nM), the capsaicin-evoked 
release was significantly reduced to 275 ± 10 and 169 ± 5 fmol/well/10min, respectively. 
The total content of CGRP in the neurons following 3 and 5 days of treatment was 1626 
± 49 and 1332 ± 47 fmol/well (Figure 6B). Thus the capsaicin-stimulated release at 3 and 5 
days of paclitaxel exposure represents 17% and 13% of the total content of CGRP, 
demonstrating that the reduced release was not secondary to changes in peptide levels.
Discussion
Research examining the effects of paclitaxel on sensory neuronal function has focused 
largely on in vivo studies using a well-characterized animal model of paclitaxel-induced 
neuropathic pain, in which integrated nociceptive withdrawal behaviors are utilized as 
indices of neuropathy (Bennett et al., 2011; Cata et al., 2008; Deng et al., 2012; Pascual et 
al., 2005; Polomano et al., 2001). Using this approach, investigators have examined the 
efficacy of antidepressants, gabapentin, COX inhibitors, antioxidants, mitochondrial 
protective agents, and immune suppressing drugs to reverse paclitaxel-induced mechanical 
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hypersensitivity and cold allodynia (Boyette-Davis et al., 2011; Flatters et al., 2006; Ito et 
al., 2012; Jin et al., 2008; Kim et al., 2010; Xiao et al., 2007). Although these putative 
therapeutics are moderately successful in the animal model, they fall short in translation into 
the clinical setting (Hershman et al., 2012; Kautio et al., 2009; Kottschade et al., 2011; Rao 
et al., 2008; Rao et al., 2007; Smith et al., 2013). These strategies largely inhibit the basal 
and pathological function of primary afferent neurons, thus the fundamental questions of 
how paclitaxel augments or reduces sensory neuronal function and whether it has dissimilar 
effects on the different subpopulations of sensory neurons have remained unanswered. 
Although Dougherty and co-workers suggest that a predominant clinical effect of the 
taxanes is on discrimination of sensations conducted by large diameter fibers (Dougherty et 
al., 2004), a role for the small diameter sensory neurons has been intimated based upon 
nociceptive endpoints (Campana et al., 1998; Polomano et al., 2001). The current findings 
demonstrate that paclitaxel can either augment or reduce TRP channel-evoked transmitter 
release from peptidergic small diameter sensory neurons dependent upon the concentration 
of the drug and the duration of exposure. A relatively low concentration of paclitaxel 
augments transmitter release, whereas a high concentration can reduce transmitter release. 
Our results are analogous to animal studies using chronic systemic injection of paclitaxel, 
which suggest that both sensitizing and desensitizing mechanisms may contribute to the 
clinical symptoms of neurotoxicity, dependent on the dosing and on the experimental 
endpoints measured.
Paclitaxel-induced increases in high extracellular potassium-stimulated release suggest that a 
gain of function is present within the small diameter peptidergic neurons and is independent 
of both TRPV1 and TRPA1. This finding also argues against a possible microtubule-induced 
defect in the synthesis and/or release of CGRP, or paclitaxel-induced neuronal death as 
potential mechanisms by which paclitaxel induces desensitization. Our findings, that 
paclitaxel treatment of sensory neuron cultures derived from adult rats does not cause 
neuronal death, contrast with findings from Scuteri and colleagues (2006), who demonstrate 
50–75% mortality of neurons within cultures derived from E16 rats following just 48 hours 
of treatment with paclitaxel. Differences in paclitaxel-induced neurotoxicity between 
sensory neurons derived from embryonic and adult DRG are not surprising, as injury to 
axons of embryonic sensory neurons induces neuronal death quicker than injury to axons of 
adult sensory neurons following axotomy (Koliatsos and Price, 1996; Whiteside et al., 
1998). The data observed from cultures of adult sensory neurons more closely mimics the 
effects of paclitaxel in an animal model of paclitaxel-induced neuropathy, where neuronal 
death is seldom observed (Polomano et al., 2001).
The mechanisms for paclitaxel-induced increases in transmitter release remain unknown, but 
the observed gain in function is supported by in vivo studies showing an augmentation in 
thermal and mechanical sensitivity. The major proposed mechanism of action for the 
oncolytic effects of paclitaxel, to bind to and alter microtubule dynamics (Manfredi et al., 
1982; Schiff et al., 1979), could result in subsequent changes in axonal trafficking (LaPointe 
et al., 2013), localization of ion channels and receptors on the plasma membrane (Gambino 
et al., 2007), and altered mitochondrial function (Kidd et al., 2002), all of which could 
contribute to enhanced neuronal sensitivity. Alternate hypotheses are that paclitaxel binds to 
other targets; as both neuronal calcium sensor-1 and Bcl-2 bind to paclitaxel and 
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subsequently disrupt neuronal calcium homeostasis and/or the function of mitochondria, 
respectively (Boehmerle et al., 2006; Ferlini et al., 2009; Voehringer, 1999). Recent work 
from Hara and co-workers indicates that systemic administration of paclitaxel in the rat 
resulted in an increase in TRPV1 mRNA and protein in the dorsal root ganglia (2013). It is 
possible that an increase in TRPV1 expression may underlie the augmentation of release in 
our neuronal cultures; however, increases in TRPV1 expression would not explain 
paclitaxel-induced sensitization of CGRP release evoked with high extracellular potassium 
or AITC. The fact that we see a reduction in capsaicin-evoked release suggests either a 
decrease in expression or a functional inhibition of TRPV1 after exposure to high 
concentrations of paclitaxel. There is a vast literature on desensitization of the TRPV1 
channels, and our future studies will examine whether desensitization mechanisms, 
established in the literature, are involved in the loss of function of TRPV1 induced by 
paclitaxel treatment.
The observation that higher concentrations of paclitaxel inhibit TRPV1-mediated activation 
of sensory neurons corroborates our previous in vivo work which showed a loss of 
capsaicin-evoked bloodflow in the dermal layers of the rat hindpaw skin after chronic 
administration of paclitaxel (Gracias et al., 2011). Furthermore, the decrease in capsaicin-
evoked release could be a mechanism to explain why thermal hyponociception is observed 
in some studies following high-dose administration of paclitaxel, while thermal hyperalgesia 
is observed in studies following low-dose treatment of the animals. For example, injecting 
16 mg/kg of paclitaxel per week for 5 weeks produced nerve degeneration with concomitant 
mechanical hyperalgesia, but thermal hypoalgesia (Authier et al., 2000). In a similar manner, 
administering 1.2 mg/kg paclitaxel 5 times per week for three weeks or a cumulative dose of 
50 mg/kg over 10 days resulted in thermal hypoalgesia in the absence of gross nerve 
degeneration (Campana et al., 1998). In contrast, administering 1mg/kg/day or 2 mg/kg/day 
on alternating days until four doses are given produced mechanical and cold allodynia and 
thermal hyperalgesia (Polomano et al., 2001). Thus, it is possible that a reduction of thermal 
nociceptive responses following high dose treatment with paclitaxel is mediated through 
losses of TRPV1 function, whereas the mechanical and cold hypersensitivity are not.
Activation of the TRPA1 channel is thought to be induced by a wide variety of stimuli, 
including noxious mechanical, noxious cold and environmental chemicals (see review by 
Kwan et al., 2006), although sensitivity of the channel to some of these stimulating 
modalities is disputed (Dunham et al., 2010). Several investigators have examined the role of 
TRPA1 in mediating paclitaxel-induced mechanical and cold allodynia by systemically 
administering a TRPA1 antagonist or by using TRPA1-deficient animals and examining the 
effects of these manipulations in animals treated with paclitaxel (Chen et al., 2011; 
Materazzi et al., 2012). Their findings suggest that TRPA1, in conjunction with another TRP 
channel, TRPV4, mediates mechanical allodynia, whereas TRPA1 alone mediates the cold 
allodynia induced by paclitaxel. These in vivo findings, demonstrating enhanced or 
sustained sensitivity of the TRPA1 channel following paclitaxel administration, contrast with 
our in vitro findings that treatment with a high concentration of paclitaxel inhibits TRPA1-
stimulated neuropeptide release. A recent series of manuscripts demonstrated that the 
TRPA1 agonist, AITC, also can activate the TRPV1 channel (Alpizar et al., 2013; Everaerts 
et al., 2011; Gees et al., 2013), suggesting that the paclitaxel-induced inhibition of AITC-
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evoked CGRP release might be mediated by the TRPV1 channel. However, evidence against 
a role for AITC in evoking CGRP release via the TRPV1 channel has been demonstrated by 
Kunkler et al., who determined that AITC-evoked release of CGRP from sensory neurons in 
culture was not inhibited by the TRPV1 antagonist, capsazepine (2011). Interestingly, a 
recent study suggests that functional TRPA1 channels, defined as those which mediate 
AITC-induced increases in intracellular calcium in cultures derived from the dorsal root 
ganglion, are expressed in both peptidergic and nonpeptidergic sensory neurons (Barabas et 
al., 2012). Thus, while we have demonstrated paclitaxel-induced inhibition of the function of 
TRPA1 channels in peptidergic neurons, persistent or enhanced activation of the TRPA1 
channels expressed within nonpeptidergic neurons could explain why desensitization to cold 
or mechanical stimulation is not observed in vivo. Further studies examining whether 
paclitaxel alters TRP-mediated increases in intracellular calcium and the release of 
glutamate will be critical to appreciate the effects of paclitaxel on TRPA1 function in the 
population of sensory neurons which does not contain CGRP.
Use of an in vitro model of paclitaxel-induced changes in neuronal sensitivity could serve as 
an alternative approach to examine mechanisms by which paclitaxel alters the function of 
sensory neurons. Although it is difficult to equate the concentrations of paclitaxel used in 
isolated cells with concentrations achieved in tissues in patients, pharmacokinetic studies 
show that dosing patients with 125–225 mg/m2 of paclitaxel results in maximal plasma 
concentrations between 1 and 10 μM (Henningsson et al., 2001; Rowinsky et al., 1999), with 
a reduction in concentration to between 0.01 μM and 1 μM by 20 hours. Furthermore, when 
paclitaxel concentrations were measured in laboratory animals 24 hours after the last of a 
number of doses, levels were significantly higher in the dorsal root ganglia and in sensory 
nerve bundles than in the plasma (Cavaletti et al., 2000; Xiao et al., 2011). Based on the 
pharmacokinetic studies in humans and the animal data suggesting that the drug 
concentrates in tissues, the amounts of paclitaxel we used in the current experiments are 
within the range that is achieved clinically.
The data in this manuscript validate the release of CGRP as a functional endpoint of sensory 
neuron activity to observe the effects of paclitaxel on neuronal function. We can use this in 
vitro model to perform interventional studies to identify and substantiate putative inhibitors 
of paclitaxel-induced PN. Further studies will elucidate different hypothesized signaling 
pathways to determine whether they contribute to the illustrated alterations in neuropeptide 
release. Paclitaxel-induced increases in neuropeptide release could contribute to a ‘gain of 
function’ of primary sensory neurons, experienced by patients as mechanical allodynia and 
tingling (Dougherty et al., 2004; Forsyth et al., 1997; Lipton et al., 1989; Wiernik et al., 
1987). Alternatively, the decreased release of neuropeptides could mediate a ‘loss of 
function’ of primary sensory neurons. A loss of sensory neuron activity could produce 
numbness (Dougherty et al., 2004) and alter the sensitivity to cold temperatures, either 
through neuronal crosstalk (McCoy et al., 2013) or via disruption of peripheral bloodflow in 
patients (Gracias et al., 2011), and therefore mediate cold-induced burning pain in patients 
(Dougherty et al., 2004; Lipton et al., 1989). Further studies are clearly needed to 
substantiate these proposed relationships between in vitro and in vivo observations. Only 
after we understand the signaling mechanisms can we subsequently develop therapeutics to 
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specifically prevent the development or maintenance of paclitaxel-induced neurotoxicity 
without compromising the oncolytic activity of the drug.
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Figure 1. 
Paclitaxel alters capsaicin-evoked release of CGRP from sensory neurons in culture. A) 
Each column represents the mean ± SEM of CGRP released in fmol/well/10 min from wells 
treated with 10 nM or 300 nM paclitaxel for 5 days. The first open column of each group 
represents basal release (B), the shaded column represents release in the presence of 30 nM 
capsaicin (C), and the second open column of each group represents the recovery of basal 
release following stimulation (B). An asterisk indicates a significant difference in capsaicin-
evoked release compared to release from the vehicle-treated neurons (p<0.05, N=9) using a 
two-way ANOVA with Bonferroni’s post-hoc test. B) Each column is the mean ± SEM of 
total CGRP content in fmol/well (N=9) from vehicle treated cultures (Veh) or paclitaxel 
treated cultures (Pac) as indicated.
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Figure 2. 
Paclitaxel alters AITC-evoked release of CGRP from sensory neurons in culture. A) Each 
column represents the mean ± SEM of CGRP released in fmol/well/10 min from wells 
treated with 10 nM or 300 nM paclitaxel for 5 days. The first open column of each group 
represents basal release (B), the shaded column represents release in the presence of 30 nM 
AITC (A), and the second open column of each group represents the recovery of basal 
release following stimulation (B). An asterisk indicates a significant difference in AITC-
evoked release compared to release from the vehicle-treated neurons (p<0.05, N=10–12) 
using a two-way ANOVA with Bonferroni’s post-hoc test. B) Each column is the mean ± 
SEM of total CGRP content in fmol/well (N=10–12) from vehicle treated cultures (Veh) or 
paclitaxel treated cultures (Pac) as indicated.
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Figure 3. 
Paclitaxel augments potassium-evoked release of CGRP from sensory neurons in culture. A) 
Each column represents the mean ± SEM of CGRP released in fmol/well/10 min from wells 
treated with 10 nM or 300 nM paclitaxel for 5 days. The first open column of each group 
represents basal release (B), the shaded column represents release in the presence of 50 mM 
KCl (HK), and the second open column of each group represents the recovery of basal 
release following stimulation (B). An asterisk indicates a significant difference in HK-
evoked release compared to release from the vehicle-treated neurons (p<0.05, N=9) using a 
two-way ANOVA with Bonferroni’s post-hoc test. B) Each column is the mean ± SEM of 
total CGRP content in fmol/well (N=9) from vehicle treated cultures (Veh) or paclitaxel 
treated cultures (Pac) as indicated.
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Figure 4. 
Paclitaxel does not decrease the survival of sensory neurons in culture. Sensory neuronal 
cultures were treated with vehicle (open columns, Veh) or with 10 nM or 300 nM paclitaxel 
for 5 days (Pac; shaded columns) and then cell viability was measured. As a positive control, 
vehicle-treated cultures were exposed to H2O2 (300 μM) for 1 hour 24 hours prior to 
analysis of cell survival (shaded columns). The number of annexin V positive cells (A) and 
propidium iodine (PI) positive cells (B) were counted in a minimum of 5 fields from 3 
different harvests and normalized to the total number of neurons in the field. Each column is 
the mean ± SEM of % of positively stained neurons. An asterisk indicates a significant 
difference from untreated controls (p<0.05, N=3) using a one way-ANOVA and 
Bonferroni’s post-hoc test.
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Figure 5. 
Paclitaxel (10 nM) increases the release of CGRP from sensory neurons in culture in a time-
dependent manner. A) Each column represents the mean ± SEM of CGRP released in fmol/
well/10 min from wells treated with vehicle or 10 nM paclitaxel for 1, 3, or 5 days as 
indicated. The first open column of each group represents basal release (B), the shaded 
column represents release in the presence of 30 nM capsaicin (C), and the second open 
column of each group represents the recovery of basal release following stimulation (B). An 
asterisk indicates a significant difference in capsaicin-evoked release compared to release 
from the vehicle-treated neurons (p<0.05, N=10–12) using a two-way ANOVA with 
Bonferroni’s post-hoc test. B) Each column is the mean ± SEM of total CGRP content in 
fmol/well (N=10–12) from cultures treated with vehicle (Veh) or paclitaxel (Pac) for the 
duration of time as indicated.
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Figure 6. 
Time-dependent effects of 300 nM paclitaxel on the release of CGRP from sensory neurons 
in culture. A) Each column represents the mean ± SEM of CGRP released in fmol/well/10 
min from wells treated with vehicle or 300 nM paclitaxel for 1, 3, or 5 days as indicated. 
The first open column of each group represents basal release (B), the shaded column 
represents release in the presence of 30 nM capsaicin (C), and the second open column of 
each group represents the recovery of basal release following stimulation (B). An asterisk 
indicates a significant difference in capsaicin-evoked release compared to release from the 
vehicle-treated neurons (p<0.05, N=10–12) using a two-way ANOVA with Bonferroni’s 
post-hoc test. B) Each column is the mean ± SEM of total CGRP content in fmol/well 
(N=10–12) from cultures treated with vehicle (Veh) or paclitaxel (Pac) for the duration of 
time as indicated. An asterisk indicates a significant difference in the total content of CGRP 
compared to the vehicle-treated cultures (p<0.05, N=10–12) using a one way-ANOVA and 
Bonferroni’s post-hoc test.
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